TokenPost·
Johnson & Johnson's JNJ-6143 Shows 75% Response Rate in Early Trial
75%
trial response rate
The oral RIPTAC small molecule was previously known as HLD-0915.
More news
- CoinGapeONDO Price Jumps as Ondo Finance Unveils Exclusive OpenAI Pre-IPO Offering
- TokenPostRoundhill PLTW Sets Weekly Distribution at $0.1161, Down 67.5%
- TokenPostAnthropic’s S-1 Lists $2.75 Million in 2025 CEO Security Costs
- Crypto BriefingGoogle DeepMind study finds LLMs can’t reliably roll their own dice
- Crypto BriefingSoFi’s tokenized deposits put banks in competition with stablecoins, Truth Ventures CEO says
- Crypto BriefingAnthropic IPO poised to deliver Menlo Ventures’ largest-ever return